Hemogenyx Pharmaceuticals (LON:HEMO) Stock Breaks Above 50-Day Moving Average – Should You Sell?

Hemogenyx Pharmaceuticals Plc (LON:HEMO) shares passed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of GBX 583.34 and traded as high as GBX 650. Hemogenyx Pharmaceuticals shares last traded at GBX 650, with a volume of 14,431 shares trading hands.

Hemogenyx Pharmaceuticals Stock Down 4.9%

The company has a market capitalization of £42.62 million, a P/E ratio of -4.72 and a beta of 1.49. The company has a 50-day moving average of GBX 583.34 and a two-hundred day moving average of GBX 753.31. The company has a quick ratio of 6.72, a current ratio of 4.04 and a debt-to-equity ratio of 42.86.

Hemogenyx Pharmaceuticals (LON:HEMO) last posted its quarterly earnings data on Monday, September 28th. The company reported GBX (101.70) earnings per share (EPS) for the quarter.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.